HQL logo

Tekla Life Sciences Investors (HQL) Financials

Balance sheets

30 Sept 202431 Mar 202430 Sept 202331 Mar 202330 Sept 202231 Mar 202230 Sept 202131 Mar 2020

Total Assets

$460.6 M(+4.2%)$441.9 M(+9.8%)$402.6 M(-7.0%)$432.7 M(+4.3%)$414.7 M(-7.5%)$448.4 M(-16.1%)$534.2 M-

Current Assets

-----$3.4 M(+2244.5%)$144.7 K-

Non Current Assets

-----$445.0 M(-16.7%)$534.0 M-

Total Liabilities

$888.6 K(+1.0%)$879.9 K(+31.9%)$667.0 K(-93.4%)$10.0 M(-40.3%)$16.8 M(+30.0%)$12.9 M(+20.4%)$10.7 M-

Current Liabilities

-----$3.5 M(+100.0%)$0.0-

Long Term Liabilities

-----$3.5 M(+100.0%)$0.0-

Shareholders Equity

$459.7 M(+4.2%)$441.1 M(+9.7%)$401.9 M(-4.9%)$422.6 M(+6.2%)$397.9 M(-8.6%)$435.5 M(-16.8%)$523.4 M-

Book Value

$459.7 M(+4.2%)$441.1 M(+9.7%)$401.9 M(-4.9%)$422.6 M(+6.2%)$397.9 M(-8.6%)$435.5 M(-16.8%)$523.4 M-

Working Capital

------$150.2 K(-203.9%)$144.7 K-

Cash And Cash Equivalents

$1.0-$477.0(-42.0%)$822.0(+84.7%)$445.0(-99.8%)$292.4 K(+29435.6%)$990.0-

Accounts Payable

$1791.0(-99.2%)$229.3 K--$5.1 M(+44.0%)$3.5 M(+100.0%)$0.0-

Accounts Receivable

-----$3.1 M(+2057.1%)$143.7 K-

Short Term Debt

-----$0.0(0%)$0.0-

Long Term Debt

-----$0.0(0%)$0.0-

Total Debt

-----$0.0(0%)$0.0-

Debt To Equity

-----0.0(0%)0.0-

Current Ratio

-----1.0--

Quick Ratio

-----1.0--

Inventory

-----$0.0(0%)$0.0-

Retained Earnings

$44.1 M(+46.2%)$30.2 M(+2138.3%)-$1.5 M(-105.5%)$26.8 M(+181.0%)$9.5 M(-82.4%)$54.3 M(-63.9%)$150.7 M-

PB Ratio

--------

Income statements

30 Sept 202431 Mar 202430 Sept 202331 Mar 202330 Sept 202231 Mar 202230 Sept 202131 Mar 2020

EPS

-------$1.3

TTM EPS

--------$0.0

Revenue

-------$2.2 M

TTM Revenue

-------$3.5 M

Total Expenses

-------$2.6 M

Operating Expenses

-------$375.9 K

Cost Of Goods Sold

-------$2.3 M

TTM Cost Of Goods Sold

-------$4.5 M

Gross Profit

--------$88.2 K

TTM Gross Profit

--------$983.7 K

Gross Margin

--------4.0%

Operating Profit

--------$464.1 K

TTM Operating Profit

--------$1.8 M

Operating Margin

--------21.3%

Net Income

-------$30.2 M

TTM Net Income

--------$1.2 M

Net Margin

-------1385.2%

EBIT

-------$60.8 M

TTM EBIT

--------$586.1 K

EBITDA

-------$60.8 M

TTM EBITDA

--------$586.1 K

Selling, General & Administrative Expenses

-------$375.9 K

TTM SG&A

-------$797.5 K

Depreciation And Amortization

-------$61.3 M

TTM D&A

-------$1.2 M

Interest Expense

-------$30.7 M

TTM Interest Expense

-------$597.5 K

Income Tax

-------$0.0

TTM Income Tax

-------$0.0

PE Ratio

--------

PS Ratio

--------

Cashflow statements

30 Sept 202431 Mar 202430 Sept 202331 Mar 202330 Sept 202231 Mar 202230 Sept 202131 Mar 2020

Cash From Operations

--------

TTM CFO

--------

Cash From Investing

--------

TTM CFI

--------

Cash From Financing

--------

TTM CFF

--------

Free Cash Flow

--------

TTM FCF

--------

CAPEX

--------

TTM CAPEX

--------

Dividends Paid

--------

TTM Dividends Paid

--------

TTM Dividend Per Share

$1.66(+24.8%)$1.33(+3.9%)$1.28(-1.5%)$1.30(-11.6%)$1.47(-10.9%)$1.65(+27.9%)$1.29(-11.6%)$1.46

TTM Dividend Yield

11.0%(+12.8%)9.8%(-2.9%)10.1%(+7.7%)9.3%(-13.3%)10.8%(+7.8%)10.0%(+61.0%)6.2%(-36.4%)9.8%

Payout Ratio

--------